William A. Weiss
William A. Weiss
Professor of Neurology, UCSF
Verified email at
Cited by
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
ZA Knight, B Gonzalez, ME Feldman, ER Zunder, DD Goldenberg, ...
Cell 125 (4), 733-747, 2006
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
BE Johnson, T Mazor, C Hong, M Barnes, K Aihara, CY McLean, ...
Science 343 (6167), 189-193, 2014
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
J Silber, DA Lim, C Petritsch, AI Persson, AK Maunakea, M Yu, ...
BMC medicine 6 (1), 1-17, 2008
Principles and current strategies for targeting autophagy for cancer treatment
RK Amaravadi, J Lippincott-Schwartz, XM Yin, WA Weiss, N Takebe, ...
Clinical cancer research 17 (4), 654-666, 2011
Targeted expression of MYCN causes neuroblastoma in transgenic mice
WA Weiss, K Aldape, G Mohapatra, BG Feuerstein, JM Bishop
The EMBO journal 16 (11), 2985-2995, 1997
Subgroup-specific structural variation across 1,000 medulloblastoma genomes
PA Northcott, DJH Shih, J Peacock, L Garzia, A Sorana Morrissy, ...
Nature 488 (7409), 49-56, 2012
Intertumoral heterogeneity within medulloblastoma subgroups
FMG Cavalli, M Remke, L Rampasek, J Peacock, DJH Shih, B Luu, ...
Cancer cell 31 (6), 737-754. e6, 2017
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
QW Fan, ZA Knight, DD Goldenberg, W Yu, KE Mostov, D Stokoe, ...
Cancer cell 9 (5), 341-349, 2006
Targeting MYCN in neuroblastoma by BET bromodomain inhibition
A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ...
Cancer discovery 3 (3), 308-323, 2013
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
SC Mack, H Witt, RM Piro, L Gu, S Zuyderduyn, AM Stütz, X Wang, ...
Nature 506 (7489), 445-450, 2014
Neuroblastoma and MYCN
M Huang, WA Weiss
Cold Spring Harbor perspectives in medicine 3 (10), a014415, 2013
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma
H Witt, SC Mack, M Ryzhova, S Bender, M Sill, R Isserlin, A Benner, ...
Cancer cell 20 (2), 143-157, 2011
Clonal selection drives genetic divergence of metastatic medulloblastoma
X Wu, PA Northcott, A Dubuc, AJ Dupuy, DJH Shih, H Witt, S Croul, ...
Nature 482 (7386), 529-533, 2012
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma
N Zhukova, V Ramaswamy, M Remke, E Pfaff, DJH Shih, DC Martin, ...
Journal of Clinical Oncology 31 (23), 2927, 2013
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Z An, O Aksoy, T Zheng, QW Fan, WA Weiss
Oncogene 37 (12), 1561-1575, 2018
Akt and autophagy cooperate to promote survival of drug-resistant glioma
QW Fan, C Cheng, C Hackett, M Feldman, BT Houseman, T Nicolaides, ...
Science signaling 3 (147), ra81-ra81, 2010
BET Bromodomain Inhibition of MYC-Amplified MedulloblastomaBET Inhibition Medulloblastoma
P Bandopadhayay, G Bergthold, B Nguyen, S Schubert, S Gholamin, ...
Clinical Cancer Research 20 (4), 912-925, 2014
Cytogenetic prognostication within medulloblastoma subgroups
DJH Shih, PA Northcott, M Remke, A Korshunov, V Ramaswamy, M Kool, ...
Journal of clinical oncology 32 (9), 886, 2014
Recognizing and exploiting differences between RNAi and small-molecule inhibitors
WA Weiss, SS Taylor, KM Shokat
Nature chemical biology 3 (12), 739-744, 2007
The system can't perform the operation now. Try again later.
Articles 1–20